Business Overview: Viridian Therapeutics, Inc. (Nasdaq: VRDN)

---

Executive Summary

Viridian Therapeutics, Inc. is a clinical/commercial-stage biopharmaceutical company developing potential best-in-class medicines for serious and rare autoimmune diseases, headquartered in Waltham, Massachusetts. The company's history traces back to a reverse merger with miRagen Therapeutics, after which it was refocused entirely on antibody therapeutics for autoimmune and rare disease indications.

Viridian's flagship program targets thyroid eye disease (TED), a serious autoimmune condition with only one FDA-approved treatment (Amgen's Tepezza). Viridian is racing to become the second approved entrant in TED with its IGF-1R antagonist antibody veligrotug, while also building an FcRn inhibitor pipeline for broader autoimmune indications and an earlier-stage TSHR inhibitor program. The company carries no approved product and no commercial revenue yet, but ended 2025 with $874.7 million in cash and investments, and has a Biologics License Application (BLA) for veligrotug under FDA Priority Review with a PDUFA target date of June 30, 2026.

---

1. Core Business Model & How They Work

Viridian is a pre-commercial biopharmaceutical company; its "revenue" today comes from partner upfront/milestone payments and a royalty-monetization deal rather than product sales. Its value creation follows the standard biotech development chain:

Antibody Discovery/Engineering ➡️ IND-Enabling Studies ➡️ Phase 1/2 Trials
        ➡️ Pivotal Phase 3 Trials ➡️ BLA/MAA Filing ➡️ FDA/EMA Approval
                ➡️ U.S. Commercial Launch (build-out underway)
                ➡️ Ex-U.S. Launch via Partners (Japan: Kissei; China: Zenas/Zai Lab)

Key mechanics of the model:

• Internally engineered antibodies. Veligrotug and its subcutaneous follow-on elegrobart (formerly VRDN-003) share the same IGF-1R binding domain but are engineered for different half-lives and routes of administration (IV vs. at-home auto-injector), letting Viridian address both acute infusion-center use and chronic maintenance dosing with one validated mechanism.
• Capital-light ex-U.S. commercialization. Rather than building global infrastructure, Viridian licensed Japan rights to Kissei Pharmaceutical (up to $70.0 million upfront, up to $315.0 million in milestones) and China rights to Zenas BioPharma (sublicensed to Zai Lab), while retaining worldwide rights excluding Japan and Greater China.
• Non-dilutive monetization of future royalties. Viridian sold U.S. revenue participation rights to DRI Healthcare for up to $300.0 million, trading future royalty economics for near-term, non-dilutive cash to fund the TED launch.
• In-house U.S. commercial build-out. The company is actively building sales, market access, patient services, and supply chain capabilities ahead of a potential 2026 U.S. launch of veligrotug.

---

2. Product Portfolio & Pipeline

---

3. Competitive Landscape

Thyroid eye disease: Amgen's Tepezza (teprotumumab) is the only FDA-approved TED therapy today and is developing an on-body subcutaneous version in Phase 3 — the benchmark Viridian must differentiate against on convenience and tolerability. Other TED-focused developers include Immunovant (batoclimab), Roche (satralizumab), Sling Therapeutics (linsitinib), Novartis (TOUR006), Lassen Therapeutics (LASN01), and Alumis (lonigutamab).

FcRn inhibition: This class already has three approved agents in generalized myasthenia gravis — argenx's Vyvgart, UCB's Rystiggo, and J&J's Imaavy — meaning Viridian's VRDN-006/VRDN-008 programs are entering a space with established, well-capitalized incumbents plus other late-stage challengers such as Immunovant (batoclimab, IMVT-1402) and J&J (nipocalimab).

TSHR inhibition: No FDA-approved therapies exist yet; named developers include GenSci (GenSci098) and AV7 Limited (K1-70), leaving this program's competitive field comparatively open but also unproven as a commercial category.

                  High Differentiation (mechanism/dosing)
                           |
      Elegrobart (SC,      |      Veligrotug (IV,
      at-home, 2nd-mover)  |      2nd-to-market, best Ph3 data)
                           |
Crowded ---------------------------------------------- Novel
(FcRn: argenx, UCB, J&J,   |      TSHR (Viridian, GenSci,
Immunovant)                |      AV7 — no approvals yet)
                           |
                  Low Differentiation

---

4. Strategic Strengths & Risks

Strengths:

• Clinical validation in TED. Both THRIVE and THRIVE-2 Phase 3 trials met primary and secondary endpoints, and FDA granted Breakthrough Therapy designation plus Priority Review — meaningfully de-risking approval relative to an earlier-stage competitor.
• Two-presentation strategy. Owning both an IV option (veligrotug, closer to launch) and a long-acting SC auto-injector option (elegrobart) lets Viridian potentially cover both acute and chronic-maintenance patients without ceding the convenience angle to a rival.
• Balance sheet strength. $874.7 million in cash/investments at year-end 2025, bolstered by the DRI royalty monetization and partner milestones, funds the commercial launch without requiring near-term dilutive financing.

Risks:

• Second-to-market dynamic. Tepezza has years of physician/payer familiarity and real-world data; Viridian must win on efficacy, safety, or convenience to take meaningful share.
• Binary regulatory and data risk. The FcRn and TSHR programs are earlier-stage, and REVEAL Phase 3 topline data for elegrobart (expected Q1/Q2 2026) is a near-term binary catalyst.
• Crowded FcRn field. Three FcRn inhibitors are already approved in at least one autoimmune indication, so VRDN-006/008 face an uphill differentiation and reimbursement fight even if clinically successful.
• Execution risk on commercial build-out. Transitioning from a clinical-stage to a commercial organization (sales force, payer access, supply chain) is a new operational discipline for the company.

---

5. Financial Overview

---

6. Summary Conclusion

Viridian is a well-capitalized, clinically de-risked biotech making a focused bet that a differentiated dosing strategy — an IV option now, a long-acting at-home SC option soon — can win meaningful share in thyroid eye disease despite arriving after Amgen's Tepezza, while its FcRn and TSHR programs offer option value in adjacent, already-competitive autoimmune categories. The single biggest near-term risk is regulatory and commercial execution risk: the veligrotug PDUFA date (June 30, 2026) and the REVEAL Phase 3 readouts are binary events that will determine whether the company's strong balance sheet translates into a durable commercial franchise or whether it remains a well-funded also-ran behind an entrenched first mover.